NCT03933033 is a NA clinical trial of Fractional Erbium Yağ Laser in Acne Vulgaris, sponsored by Aswan University Hospital.

Who is sponsoring NCT03933033?

NCT03933033 is sponsored by Aswan University Hospital.

What drugs are being tested in NCT03933033?

Interventions in NCT03933033: Fractional Erbium Yağ Laser, Platelet Rich Plasma.

What condition does NCT03933033 study?

NCT03933033 studies Acne Vulgaris, Scars.

Is NCT03933033 still recruiting?

NCT03933033 is currently completed. Last updated 1 May 2019.

Last reviewed 2019-05-01 · How we verify

NCT03933033

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Erbium-YAG Laser Versus Platelet Rich Plasma in the Treatment of Atrophic Acne Scars

Completed NA Last updated 1 May 2019

What this trial tests

NA trial testing Fractional Erbium Yağ Laser in Acne Vulgaris in 75 participants. Completed in 28 February 2019.

Timeline

1 June 2017

Primary endpoint
31 August 2018

28 February 2019

Quick facts

Lead sponsor	Aswan University Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	75
Start date	1 June 2017
Primary completion	31 August 2018
Estimated completion	28 February 2019
Sites	1 location across Egypt

Drugs / interventions tested

Fractional Erbium Yağ Laser
Platelet Rich Plasma — full drug profile →

Conditions studied

Acne Vulgaris — all drugs for Acne Vulgaris →
Scars — all drugs for Scars →

Sponsor

Aswan University Hospital

Who can join

Adults 18 to 38, any sex, with Acne Vulgaris or Scars. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aim to assess the efficacy of Er-YAG laser 2940nm and PRP as a single line of treatment in comparison with combined treatment in atrophic post acne scars.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Fractional Erbium-YAG Laser and Platelet-Rich Plasma as Single or Combined Treatment for Atrophic Acne Scars: A Randomized Clinical Trial.
El-Taieb MA, Ibrahim HM, Hegazy EM, Ibrahim AK, et al · · 2019 · cited 20× · PMID 31420849 · DOI 10.1007/s13555-019-00318-1

Verify or expand the search:

Other recruiting trials for Acne Vulgaris

Currently open trials in the same condition.

NCT07341087 — Skin Inflammation in Perimenopause: A Probiotic Intervention Proof of Concept Trial · NA · recruiting
NCT07474883 — Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris · EARLY_PHASE1 · recruiting
NCT07186413 — A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne · Phase 3 · recruiting
NCT07056673 — Cold Atmospheric Plasma for Moderate-to-severe Acne Vulgaris Study · NA · recruiting
NCT07102186 — Efficacy and Safety of Adapalene Gel and Hyaluronic Acid Versus Adapalene Gel Alone in Mild to Moderate Acne Vulgaris · Phase 4 · recruiting

Other Aswan University Hospital trials

Trials by the same sponsor.

NCT06491394 — Lactoferrin Effect on Kidney and Heart of Rhabdomyolysis Rats · Phase 4 · completed
NCT06211088 — Famotidine Versus Placebo in Emergency Pediatric Surgery As a Risk to Postoperative Nausea and Vomiting · NA · completed
NCT06583590 — Evaluation of Efficacy of Botulinum Toxin A Plus Oral Tadalafil 5 mg in Diabetic Men With Erectile Dysfunction · Phase 2, PHASE3 · recruiting
NCT06537323 — Femoral Nerve Block, Periarticular Nerve Group (PENG) Block, and Preoperative IV Fentanyl · NA · recruiting
NCT06535256 — Compare Intraperitoneal Instillation of Bupivacaine+dexmedetomidine Versus Bupivacaine+dexamethasone on Postoperative Pa · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03933033 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aswan University Hospital
Last refreshed: 1 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03933033.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing